Shore Capital Reiterates “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat Ratings reports.

A number of other analysts have also recently weighed in on AZN. Barclays reiterated an “overweight” rating and set a £125 ($161.67) price target on shares of AstraZeneca in a research note on Monday, April 8th. Jefferies Financial Group upped their price objective on shares of AstraZeneca from GBX 71 ($0.92) to GBX 74 ($0.96) and gave the stock a “hold” rating in a research report on Tuesday, July 2nd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($142.27) price objective on shares of AstraZeneca in a research report on Tuesday, June 18th. Finally, Berenberg Bank upped their price objective on shares of AstraZeneca from £130 ($168.13) to £150 ($194.00) and gave the stock a “buy” rating in a research report on Friday, June 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of £105.53 ($136.49).

AstraZeneca Stock Up 1.0 %

Shares of LON:AZN opened at £121.80 ($157.53) on Thursday. The stock has a market cap of £188.79 billion, a P/E ratio of 3,903.85, a P/E/G ratio of 0.97 and a beta of 0.16. The firm has a fifty day moving average price of £122.73 and a 200 day moving average price of £112.93. The company has a debt-to-equity ratio of 92.51, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 1-year low of GBX 9,461 ($122.36) and a 1-year high of £127.04 ($164.30).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.